194 results
424B4
SNGX
Soligenix Inc
19 Apr 24
Prospectus supplement with pricing info
4:05pm
in the first successful Phase 3 FLASH study that consisted of three 6-week treatment cycles (18 weeks total), with the primary efficacy assessment occurring … -controlled assessment to 18 weeks of continuous treatment (no “between-Cycle” treatment breaks) with the primary endpoint assessment occurring
8-K
EX-99.2
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
as assessed by Composite Assessment of Index Lesion Severity (CAILS) score for 3 index lesions at the end Cycle 1 (week 8) o Cycle 2 complete
8-K
EX-99.1
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
cycles (18 weeks total), with the primary efficacy assessment occurring at the end of the initial 6 week double-blind, placebo-controlled treatment … cycle (Cycle 1). However, the second study extends the double-blind, placebo-controlled assessment to 18 weeks of continuous treatment (no “between
8-K
EX-99.1
k0v5odsjikgcd
19 Dec 22
Other Events
8:00am